Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

P. Wright, M. Birkett, S. R. David, K. Meehan, I. Ferchland, K. J. Alaka, J. C. Saunders, J. Krueger, P. Bradley, L. San, M. Bernardo, M. Reinstein, A. Breier

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

Original languageEnglish (US)
Pages (from-to)1149-1151
Number of pages3
JournalAmerican Journal of Psychiatry
Volume158
Issue number7
DOIs
StatePublished - Jul 19 2001

Fingerprint

olanzapine
Haloperidol
Schizophrenia
Placebos
Therapeutics
Injections
Dystonia
Intramuscular Injections
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. / Wright, P.; Birkett, M.; David, S. R.; Meehan, K.; Ferchland, I.; Alaka, K. J.; Saunders, J. C.; Krueger, J.; Bradley, P.; San, L.; Bernardo, M.; Reinstein, M.; Breier, A.

In: American Journal of Psychiatry, Vol. 158, No. 7, 19.07.2001, p. 1149-1151.

Research output: Contribution to journalArticle

Wright, P, Birkett, M, David, SR, Meehan, K, Ferchland, I, Alaka, KJ, Saunders, JC, Krueger, J, Bradley, P, San, L, Bernardo, M, Reinstein, M & Breier, A 2001, 'Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia', American Journal of Psychiatry, vol. 158, no. 7, pp. 1149-1151. https://doi.org/10.1176/appi.ajp.158.7.1149
Wright, P. ; Birkett, M. ; David, S. R. ; Meehan, K. ; Ferchland, I. ; Alaka, K. J. ; Saunders, J. C. ; Krueger, J. ; Bradley, P. ; San, L. ; Bernardo, M. ; Reinstein, M. ; Breier, A. / Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. In: American Journal of Psychiatry. 2001 ; Vol. 158, No. 7. pp. 1149-1151.
@article{bd07ef712b89484ba600ba230832778e,
title = "Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia",
abstract = "Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7{\%} of those who were treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.",
author = "P. Wright and M. Birkett and David, {S. R.} and K. Meehan and I. Ferchland and Alaka, {K. J.} and Saunders, {J. C.} and J. Krueger and P. Bradley and L. San and M. Bernardo and M. Reinstein and A. Breier",
year = "2001",
month = "7",
day = "19",
doi = "10.1176/appi.ajp.158.7.1149",
language = "English (US)",
volume = "158",
pages = "1149--1151",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "7",

}

TY - JOUR

T1 - Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

AU - Wright, P.

AU - Birkett, M.

AU - David, S. R.

AU - Meehan, K.

AU - Ferchland, I.

AU - Alaka, K. J.

AU - Saunders, J. C.

AU - Krueger, J.

AU - Bradley, P.

AU - San, L.

AU - Bernardo, M.

AU - Reinstein, M.

AU - Breier, A.

PY - 2001/7/19

Y1 - 2001/7/19

N2 - Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

AB - Objective: The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia. Method: Hospitalized patients with schizophrenia received one to three injections of intramuscular olanzapine, 10 mg, intramuscular haloperidol, 7.5 mg, or intramuscular placebo over a 24-hour period. Agitation was measured with the excited component of the Positive and Negative Syndrome Scale and two additional scales. Results: According to scores on the excited component of the Positive and Negative Syndrome Scale, both intramuscular olanzapine and intramuscular haloperidol reduced agitation significantly more than intramuscular placebo 2 and 24 hours following the first injection. Intramuscular olanzapine reduced agitation significantly more than intramuscular haloperidol 15, 30, and 45 minutes following the first injection. No patients treated with intramuscular olanzapine experienced acute dystonia, compared with 7% of those who were treated with intramuscular haloperidol. No significant QTc interval changes were observed in any patients. Conclusions: Intramuscular olanzapine represents a rapid, effective, and safe treatment for acute agitation in schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0034935303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034935303&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.158.7.1149

DO - 10.1176/appi.ajp.158.7.1149

M3 - Article

C2 - 11431240

AN - SCOPUS:0034935303

VL - 158

SP - 1149

EP - 1151

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 7

ER -